1. bookVolumen 24 (2016): Edición 3 (September 2016)
Detalles de la revista
License
Formato
Revista
eISSN
2284-5623
Primera edición
08 Aug 2013
Calendario de la edición
4 veces al año
Idiomas
Inglés
access type Acceso abierto

Evaluation of thrombin generation in classical Philadelphianegative myeloproliferative neoplasms / Evaluarea generării trombinei în neoplasmele mieloproliferative Philadelphia- negative

Publicado en línea: 15 Oct 2016
Volumen & Edición: Volumen 24 (2016) - Edición 3 (September 2016)
Páginas: 279 - 289
Recibido: 04 Mar 2016
Aceptado: 02 Jul 2016
Detalles de la revista
License
Formato
Revista
eISSN
2284-5623
Primera edición
08 Aug 2013
Calendario de la edición
4 veces al año
Idiomas
Inglés
Abstract

Introduction: Patients with Philadelphia-negative chronic myeloproliferative neoplasms (Ph-MPN), polycytemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF), are prone to develop thrombotic events. We aimed to investigate the coagulation status in their plasma using thrombin generation assay (TGA), a functional global assay, on Ceveron® Alpha.

Materials and methods: The samples were collected from 89 consecutive Ph-negative MPN patients and from 78 controls into K2EDTA and CTAD tubes for blood cell counts, TGA and coagulation screening tests. Thrombin generation was analysed in platelet-poor plasma using Technothrombin® TGA assay kit.

Results: We found a significantly increased peak thrombin generation (p=0.049) and velocity index (VI) (p=0.012) in patients in comparison with controls, especially in ET patients, and a significantly higher values for peak thrombin (p=0.043) and VI (p=0.042) in patients receiving anagrelide in comparison with those treated with hydroxyurea. We also noticed an inverse correlation between the length of cytoreductive therapy and TGA parameters, (peak thrombin R=-0.25, p=0.018, AUC R=-0.257, p=0.015, and VI R=-0.21, p=0.048).

Conclusion: Our results suggest that Ph-MPN patients, and especially those with ET, are predisposed to thrombotic events due to their higher peak thrombin and VI values and their risk may decreases as treatment is longer. Patients treated with hydroxyurea generate less thrombin and could be less prone to develop thrombotic events in comparison with those treated with anagrelide.

Keywords

1. Vardiman JW, Brunning RD, Arber DA, Lebean MM, Porurt A, Telferi A, et al. Introduction and Overview of the Classification of the Myeloid Neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. IARC, Lyon. 2008; 18-49.Search in Google Scholar

2. Campbell PJ, Green AR. The myeloproliferative disorders.N Engl J Med. 2006 Dec; 355(23):2452-66. DOI: 10.1056/NEJMra063728.10.1056/NEJMra063728Search in Google Scholar

3. Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2012 Dec;2012(1):571-81.10.1182/asheducation.V2012.1.571.3798557Search in Google Scholar

4. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013 Mar;122(13):2176-84. DOI: 10.1182/blood-2013-03-460154.10.1182/blood-2013-03-460154Search in Google Scholar

5. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Apr;7(4):387-97. DOI: 10.1016/j.ccr.2005.03.023.10.1016/j.ccr.2005.03.023Search in Google Scholar

6. Marchetti M, Castoldi E, Spronk HMH, van Oerle R, Baldicci D, Barbui T, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood. 2008 Nov;112(10):4061-8. DOI: 10.1182/ blood-2008-06-164087.10.1182/blood-2008-06-164087Search in Google Scholar

7. Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Büller HR, Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythemia and idiopatic myelofibrosis: a systematic review. Thromb Res. 2009 Sep;124(4):409-17. DOI: 10.1016/j.thromres.2009.02.004.10.1016/j.thromres.2009.02.004Search in Google Scholar

8. Tripodi A, Chantarangkul V, Gianniello F, Clerici M, Lemma L, Padovan L, et al. Global coagulation in myeloproliferative neoplasms. Annals of Hematology. 2013 Dec;92(12):1633-9. DOI: 10.1007/s00277-013-1834-x.10.1007/s00277-013-1834-xSearch in Google Scholar

9. Castoldi E, Rosing J. Thrombin generation tests. Thromb Res. 2011 Feb;127(Suppl3): S21-5. DOI: 10.1016/S0049-3848(11)70007-X.10.1016/S0049-3848(11)70007-XSearch in Google Scholar

10. Thiele J, Imbert M, Pierre R, Vardiman JW, Brunning RD, Flandrin G. Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:35-8.Search in Google Scholar

11. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zang L. et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005 Sep;106(6):2162-68. DOI: 10.1182/ blood-2005-03-1320.10.1182/blood-2005-03-132015920007Search in Google Scholar

12. Ten Caten H. Thrombin generation in clinical conditions. Thromb Res. 2012 Mar;126(3):367-70. DOI: 10.1016/j.thromres.2011.10.01710.1016/j.thromres.2011.10.01722079443Search in Google Scholar

13. Duchemin J, Ugo V, Ianotto JC, Lecucq L, Mercier B, Abgrall JF. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res. 2010 Sep(3);126:238-42. DOI: 10.1016/j.thromres.2010.06.025.10.1016/j.thromres.2010.06.02520656333Search in Google Scholar

14. Trappenburg MC, van Schilfgaarde M, Marchetti M, Spronk HM, ten Cate H, Leyte A et al. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica. 2009 Jul;94(7):911-8. DOI: 10.3324/haematol.13774.10.3324/haematol.13774270430119508974Search in Google Scholar

15. Campbell PJ, MacLean C, Beer PA, Buck G, Weathley K, Kiladjian JJ et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood. 2012 Aug;120(7):1409-11. DOI: 10.1182/ blood-2012-04-424911.10.1182/blood-2012-04-424911347093622709688Search in Google Scholar

16. Passamonti F, Rumi E, Pascutto C, Cazzola M, Lazzarini M. Increase in leucocyte count over tome predicts thrombosis in patients with low-risk essential thrombocythemia. Thromb Haemost. 2009 Sep;7(9):1587-9. DOI: 10.1111/j.1538-7836.2009.03531.x.10.1111/j.1538-7836.2009.03531.x19566793Search in Google Scholar

17. Panova-Noeva M, Marcetti M, Buoro S, Russo L, Leuzzi A, Finazzi G, et al. Jak2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood. 2011Sep;118(9):2599-601. DOI: 10.1182/blood-2011-02-339655.10.1182/blood-2011-02-33965521750318Search in Google Scholar

18. Olteanu AL, Mihaila RG, Catana AC, Flucus O, Bus C, Mihalache M. Platelet indices in Philadelphia-negative chronic myeloproliferative neoplasms. Rev Romana Med Lab. 2015;23(2):169-77. DOI:10.1515/rrlm-2015-0012.10.1515/rrlm-2015-0012Search in Google Scholar

19. Carrobbio A, Finazzi G, Antonioli E, Vannucchi AM, Barosi G, Ruggeri M, et al. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responce by European Leukemianet criteria.Blood. 2010 Aug;116(7):1051-5. DOI: 10.1182/ blood-2010-03-272179.10.1182/blood-2010-03-27217920479281Search in Google Scholar

20. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high risk essential thrombocythemia. N Engl J Med. 2005 Jul;353(1):33-45. DOI: 10.1056/ NEJMoa043800.10.1056/NEJMoa04380016000354Search in Google Scholar

21. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J,Kvasnicka HM,et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar;121(10):1720-8. DOI: 10.1182/blood-2012-07-443770.10.1182/blood-2012-07-443770359179623315161Search in Google Scholar

22. Barbui T, Finazzi G, Carrobio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization – essential thrombocythemia (IPSET-thrombosis). Blood. 2012 Dec; 120(26):5128-33. DOI: 10.1182/blood-2012-07-444067.10.1182/blood-2012-07-44406723033268Search in Google Scholar

23. Coucelo M, Caetano G, Sevivas T, Almeida Santos S, Fidalgo T, Bento C et al. JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients. Int J Hematol. 2014 Jan;99(1):32-40. DOI: 10.1007/s12185-013-1475-9. 10.1007/s12185-013-1475-924277659Search in Google Scholar

Artículos recomendados de Trend MD

Planifique su conferencia remota con Sciendo